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Abstract 
Background 
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, 
characterized by largely unsatisfactory responses to the currently available therapeutic 
strategies. In this study we evaluated the expression of genes involved in gemcitabine uptake 
in a selected cohort of patients with PDAC, with well-defined clinical-pathological features. 
Methods 
mRNA levels of hENT1, CHOP, MRP1 and DCK were evaluated by means of qRT-PCR in 
matched pairs of tumor and adjacent normal tissue samples collected from PDAC patients 
treated with gemcitabine after surgical tumor resection. To detect possible interaction 
between gene expression levels and to identify subgroups of patients at different 
mortality/progression risk, the RECursive Partitioning and Amalgamation (RECPAM) 
method was used. 
Results 
RECPAM analysis showed that DCK and CHOP were most relevant variables for the 
identification of patients with different mortality risk, while hENT1 and CHOP were able to 
identify subgroups of patients with different disease progression risk. Conclusion: hENT1, 
CHOP, MRP1 and DCK appear correlated to PDAC, and this interaction might influence 
disease behavior. 
Keywords 
Pancreatic ductal adenocarcinoma, hENT1, CHOP, MRP1, DCK, RECPAM 
Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death 
[1,2] with a poor prognosis due to the early undetectable symptoms and the lack of effective 
treatment which are responsible for the high lethality [3,4]. There is an urgent need for 
additional biomarkers which can predict the PDAC onset, or for implementing new effective 
therapeutic strategies. Gemcitabine is considered the standard of care for the treatment of 
patients with locally advanced and metastatic PDAC, with either curative or palliative intent 
[5,6]. Gemcitabine was synthesized in early 1980s and chemically is a nucleoside analogue 
(similar to cytosine) which displays two fluorines on the carbon 2′, instead of the hydrogen 
atoms, conferring it tumor growth arrest properties. 
Recently, research efforts were boosted in order to find biomarkers effective into predict the 
clinical benefits of gemcitabine in PDAC [7,8]. Among the factors involved in the 
gemcitabine response pathway, human equilibrative nucleoside transporter 1 (hENT1) has 
been reported as the main mediator of gemcitabine uptake across plasma membranes [9], and 
it has been associated to gemcitabine-dependent effects in several in vitro and in vivo studies 
[10-14]. The deoxycytidine kinase (DCK), represents another key enzyme involved in 
gemcitabine phosphorylation/activation, and it has also been implicated in gemcitabine 
resistance [15], as well as the multidrug resistance-associated protein 1 (MRP1) which is 
involved in chemotherapy resistance in human pancreatic cancer [16,17]. Further, CCAAT-
enhancer-binding protein homologous protein (CHOP) represents a stress-induced 
transcription factor involved not only in the cell cycle and apoptosis [18], but also in the 
transcriptional down-regulation of hENT1 expression [19]. 
Herein we analyzed potential changes in the expression levels of hENT1, DCK, MRP1 and 
CHOP, as are the main factors involved in the gemcitabine response pathway and they are 
involved in gemcitabine uptake and activation, in biopsies of PDAC patients in order to find 
possible associations between the mutual expression levels of these genes and clinical 
pathological features in a selected and well characterized cohort of patients with PDAC. 
Material and methods 
Clinical samples 
The training cohort included tissues specimens collected from 26 patients with pancreatic 
ductal adenocarcinoma (PDAC). These patients were selected among a total of 76 subjects, 
with final pathological diagnosis of PDAC, who underwent pancreatic resection and at our 
hospital IRCCS “Casa Sollievo della Sofferenza” San Giovanni Rotondo (Italy), between 
March 2008 and May 2014. The inclusion criteria included: availability of matched pairs of 
tumor and adjacent normal tissue sample (54 out of 76), adjuvant chemotherapy with 
gemcitabine administered after complete resection of pancreatic cancer in absence of neo-
adiuvant treatments (26 out of 54), and complete follow-up data, including either clinical 
examination of CA 19–9 serum marker and monitor of response to treatment at regular 
intervals (26 out of 26). In details, all the 26 patients fulfilling these criteria, weekly received 
gemcitabine at a dose of 1,000 mg/m2 for 7 weeks as an induction phase. After this phase, 
CA 19–9 levels were elevated in 10 patients. This patients underwent to computed 
tomography scan that showed visceral metastases (liver, mesenteric, lung etc.), therefore 
were evaluated for a first line treatment. The remaining patients with normal CA 19–9 levels, 
entered the chemoradiotherapy phase of the treatment. In five patients, gemcitabine 400 
mg/m2 weekly × 3 every 28 days for 2 cycles, and concurrent radiotherapy, for a total dose of 
50.4 Gy in 28 fractions were prescribed. In one patient, at the end of radiotherapy, 
gemcitabine was continued as maintenance. The others 8 patients received only gemcitabine 
at the same doses above-mentioned without radiotherapy. The study was approved by the 
hospital ethical committee. Tissue specimens were immediately frozen in liquid nitrogen, and 
stored at −80 °C until RNA extraction. All the patients signed the informed consent before 
tissues collection. Demographics and clinical-pathological characteristics of patients are 
listed in Table 1. 
  
Table 1 Clinical and pathological features of 26 patients with Pancreatic Ductal Adenocarcinoma treated with 
Gemcitabine after pancreatic resection 
Age at diagnosis (years), median (Q1-Q3) 64.5 (51–73) 
Gender, male/female (%male) 17/9 (65) 
Smoking habit, n (%)  
    No 10 (48) 
    Yes 8 (38) 
    Ex 3 (14) 
Missing information 5 
Alcohol Use, n (%)  
    No 18 (95) 
    Yes 1 (5) 
Missing information 7 
Jaundice, y/n (%y) 15/11 (58) 
Diabetes mellitus, y/n (%y) 9/17 (35) 
Familial*, y/n (%y) 5/21 (19) 
Previous Neoplasia, y/n (%y) 2/24 (8) 
Preoperative serum CAE levels (ng/ml), median (Q1-Q3) 3.2 (2.0-6.0) 
Preoperative serum CA 19–9 levels (U/ml), median (Q1-Q3) 200.4 (53.5-335.9) 
Size (cm), median (Q1-Q3) 3 (2.4-3.5) 
Tumour type, n (%)  
    Adenocarcinoma 22 (85) 
    Adenocarcinoma Mucinous 4 (15) 
Tumour grading, n (%)  
    G1: well differentiated 5 (20) 
    G2: moderately differentiated 10 (40) 
    G3: poorly differentiated 10 (40) 
Missing information 1 
T: Tumour size, n (%)  
    T1 1 (4) 
    T2 2 (8) 
    T3 23 (88) 
N: regional lymph nodes, n (%)  
    N0 3 (12) 
    N1 23 (88) 
Lymph nodes ratio, median (Q1-Q3) 0.24 (0.07-0.47) 
Tumour stage, n (%)  
    IIA 3 (12) 
    IIB 23 (88) 
Perineural Invasion, y/n (% y) 14/12 (54) 
Vascular Invasion, y/n (% y) 3/23 (12) 
Margins of resection, n (%)  
    R0: negative resection margins 18 (69) 
    R1: microscopic positive resection margins 8 (31) 
Postoperative serum CAE levels (ng/ml), median (Q1-Q3) 3.4 (2.0-4.5) 
Postoperative serum CA 19–9 levels (U/ml), median (Q1-Q3) 10.4 (7.3-36.2) 
Treatment with Gemcitabine  
    Nr. Cycles, median (Q1-Q3) 5 (3–7) 
    Nr. Cycles < 6, n (%) 10 (39) 
Nr. Cycles > 6, n (%) 16 (62) 
Overall Follow-up (yrs), median (Q1-Q3) 1.4 (0.9-2.3) 
Disease progression Follow-up (yrs), median (Q1-Q3) 0.9 (0.6-1.3) 
Mortality rate** 16/45 (35) 
Disease Progression rate** 17/29 (58) 
* For neoplasia or chronic pancreatitis; ** Number of events/person-years (expected number of events per 100 
person-years). 
RNA isolation 
Cryostat representative sections of the tumor were morphologically evaluated and neoplastic 
cellularity was enriched by microdissection of the most cellular areas. Total RNA was 
extracted from fresh frozen specimens by means of TRIzol® Reagent (Invitrogen, Milano, 
Italy) and subsequently purified using RNeasy®Mini Kit and digestion with DNase I. 
(Qiagen, Milano, Italy), according to manufacturer’s recommendations. RNA concentration 
and purity (A260:A280 > 2.0; A260/A230 > 1.8) were controlled by NanoDrop 
Spectrophotometer (Thermo Fisher, Waltham, MA, USA). 
Quantitative Real Time PCR 
Expression analyses were performed using QuantiFast Sybr Green PCR kit (Qiagen, Milano, 
Italy), following the one-step protocol: cDNA was first synthesized from 60 ng total RNA, 
and then amplified by means of the Sybr Green QuantiTect Primer (Qiagen, Milano, Italy): 
hENT1 (QT010000083), CHOP (QT00082278), MRP1 (QT00061159) and DKC 
(QT00000392). Reactions were set up in 96-well plates and loaded onto 7700 Real-Time 
PCR System (Applied Biosystems, Foster City, CA). Optical data obtained were analyzed 
using the SDS software package (version 1.9.1; Applied Biosystems, Foster City, CA). 
Expression levels of target gene were obtained using the comparative method of relative 
quantification, after normalization for the housekeeping control gene Glyceraldehyde-3-
phosphate dehydrogenase GAPDH (Sigma Aldrich, Milano, Italy), as previously performed 
[20]. 
Immunohistochemistry 
Formalin-fixed, paraffin-embedded PDAC sections were immunostained as already described 
[21] by using iVIEW DAB Detection Kit for Ventana BenchMark XT automated slide stainer 
on human biopsies. Primary antibodies for hENT1 was purchased from Santacruz (cat. n. sc-
134501) and diluted 1:100. Appropriate positive controls, as well as non-immune serum for 
negative controls, were run concurrently. 
Normal pancreatic tissue samples were obtained from OriGene (Rockville, MD, USA) 
http://www.origene.com/tissue/tissue_qc.aspx. hENT1 immunoreactivity was evaluated in 
blind by two expert pathologists (FR and FC) assessing a semiquantitative scoring system in 
ten high power fields (10HPF, X 400) according to a semiquantitative scale (−: 0%; +: 1-
33%; ++: 34-66%; +++: 67-100%). 
Statistical methods 
Baseline patients’ characteristics were reported as frequency (percentages) and mean ± 
standard deviation (SD), along with median and lower (Q1) and upper (Q3) quartiles range, 
for categorical variables and continuous variables, respectively. Normal distribution 
assumption was checked by means of Q-Q plot, Shapiro-Wilks and Kolmogorov-Smirnov 
tests. To assess the presence of down/over regulation of genes expression in tumors compared 
to normal samples, one-sample t-test was performed using logarithm-transformed gene 
expression values. Correlations between (log-transformed) gene expression levels were 
assessed estimating Pearson’s correlation coefficients (r), whereas comparisons between log-
transformed gene expression levels and categorical clinical variables were assessed using 
two-sample t-test or ANOVA models, respectively. Time to disease progression was defined 
as the time between the date of the surgery (baseline) and the date of the first progression 
event. Time to death was defined as the time between the baseline and the date of death. For 
subjects who did not experience any event, time variable was defined as the time between the 
baseline and the date of the last available clinical follow-up. 
Incidence rates for events (i.e. disease progression or death, separately) were calculated as the 
number of events divided by the estimated persons-years, and eventually multiplied by 100. 
To evaluate interactions between hENT1, CHOP, DCK, MRP1 genes only, and between 
hENT1, CHOP, DCK, MRP1 genes along with all patients’ clinical variables, identifying 
distinct and homogeneous subgroups of patients in terms of progression-free survival (PFS) 
and overall survival (OS), the RECursive Partitioning and AMalgamation (RECPAM) 
method was used [22,23]. The tree-growing algorithm estimates hazard ratios (HR), along 
with 95% confidence interval (95%CI), from a Cox proportional hazards regression model 
using appropriate covariates, as candidate splitting variables. 
At each partitioning step, the method chooses the covariate and its best binary split to 
maximize the difference in the outcome of interest (i.e. PFS or OS). The algorithm stops 
when user defined conditions (stopping rules) are met (i.e. at least one event and at least three 
subjects per leaf). To obtain more robust and stable split (cut-off), a permutation approach 
was adopted to choose the best splitting variable. Furthermore, survival curves were drawn, 
for each final RECPAM class, from Cox proportional hazard models. 
Moreover, all clinical features which could affect PDAC risk and clinical outcome of patients 
(i.e. diabetes mellitus, family history for neoplasia, tumor stage, positive surgical margins of 
resection, presence of vascular invasion, number of cycles of treatment with gemcitabine.) 
were compared between final RECPAM classes, using the Kruskal-Wallis and Fisher exact 
tests (due to non-normal data distribution and small sample size) for continuous and 
categorical variables, respectively. 
A p value <0.05 was considered for statistical significance. All analyses were performed 
using SAS Release 9.3 (SAS Institute, Cary, NC, USA). For the RECPAM analysis a SAS 
macro routine, written by one of the authors (F. Pellegrini), was used. 
Results 
Relative expression levels of hENT1, CHOP, MRP1 and DCK in PDAC 
biopsies 
Looking at median of gene expression levels in tumors compared to adjacent normal tissues, 
hENT1 down-regulation in tumor samples was found (fold-change = 0.53, Q1-Q3 = 0.23-
0.94, p = 0.006), (Figure 1). No differences in CHOP, MRP1 and DCK expression levels 
were observed in tumors compared to normal tissues (CHOP: fold-change = 1.02, Q1-Q3 = 
0.16-2.02, p = 0.266; MRP1: fold-change = 0.58, Q1-Q3 = 0.22-1.21, p = 0.203; DCK fold-
change = 1.15, Q1-Q3 = 0.28-2.36, p = 0.370) Figure 1. Furthermore, MRP1 expression 
levels were significantly correlated with those of both hENT1 (r = 0.53, p = 0.006) and 
CHOP (r = 0.42, p = 0.032). 
Figure 1 Boxplot of relative expression levels of hENT1, CHOP, MRP1 and DCK in 
matched pairs of tumor and normal samples from patients with Pancreatic Ductal 
Adenocarcinoma. Each box highlights median (horizontal black bar), interquartile range 
(Q1-Q3) and lower and upper adjacent values (vertical bars) for each gene. Genes expression 
values are reported in log scale (y-axis). * p < 0.001. 
Associations with clinical phenotypes 
To establish whether mRNA levels were associated with specific diseases phenotypes, we 
analyzed the possible associations of genes expression with age at diagnosis, gender, smoking 
habit, alcohol use, presence of jaundice, diabete mellitus, family history for neoplasia, serum 
levels of carcinoembryonic antigen (CEA), tumor markers, tumor grading, tumor size, tumor 
histological type, lymph node spreading, staging of tumor, resection margins and medical 
therapy. In details, levels of hENT1 were associated with jaundice and the resection margins 
of patients at diagnosis. hENT1 resulted differentially expressed in jaundiced patients 
compared to those without jaundice (jaundiced: fold-change = 0.61, Q1-Q3 = 0.32-1.76 vs 
not jaundiced: fold-change = 0.25, Q1-Q3 = 0.11-0.84; p = 0.047), and was differentially 
expressed in patients with evidence of tumor infiltration of the resection margins (R1) with 
respect to those with resection margins free from tumor cells (R0), (R1: fold-change = 1.35, 
Q1-Q3 = 0.32-2.37 vs R0: fold-change = 0.51, Q1-Q3 = 0.21-0.77; p = 0.030) showing a 
trend without reaching a statistical significance for the age (hENT1: r = 0.36, p = 0.067). 
CHOP resulted down-regulated in patients with family history of cancer (F1: fold-change = 
0.11, Q1-Q3 = 0.09-0.16 vs F0: fold-change = 1.23, Q1-Q3 = 0.24-2.39; p = 0.044) and over-
expressed in patients who had a previous neoplasia (PN1: fold-change = 31.77, Q1-Q3 = 
1.57-61.98 vs PN0: fold-change = 0.66, Q1-Q3 = 0.13-1.93; p = 0.033). Interestingly, 
expression levels of DCK were found down regulated in mucinous adenocarcinoma (AM: 
fold change = 0.36, Q1-Q3 = 0.14-0.57 vs A: fold change = 1.34 Q1-Q3 = 0.34-2.94 p = 
0.016). Finally, MRP1 expression did not show any statically significant association with the 
clinical phenotypes taken in consideration. 
Survival analysis 
In the overall sample, 16/26 (61.5%) patients died during the follow-up and 17/26 (65.3%) 
had a disease progression. Specifically, the overall mortality rate was 35 events per 100 
person/years (median follow-up of 1.4 years), whereas the overall disease progression rate 
was 58 events per 100 person/years (median follow-up of 0.9 years). 
Focusing on the investigation of interactions between hENT1, CHOP, MRP1 and DCK genes 
on OS and PFS outcome, RECPAM tree-growing algorithm identified three classes at 
different mortality risks. As shown in Figure 2A, the reference class (Class 3) is represented 
by the subgroup with the lowest mortality, and all the HRs are estimated with respect to this 
reference class. In details, patients with DCK values ≤0.27 (n = 6) identified the reference 
class (HR = 1), whereas those with DCK > 0.27 and CHOP ≤ 0.25 (n = 6) identified the class 
with the highest mortality risk (Class 1, HR = 9.10, 95%CI = 1.50-55.04). Furthermore, 
patients with DCK > 0.27 and CHOP > 0.25 (n = 14) identified the intermediate risk class 
(Class 2, HR = 3.23, 95%CI = 0.64-16.23). The overall mortality rates (reported as the 
number of events per 100 person-years), along with median follow-up time, were: 63 (16.3 
months), 35 (13.7 months), 23 (35.4 months) for Classes 1,2 and 3, respectively. (Figure 2A). 
Figure 2 Identification of subgroups at different risks based on gene-expression 
interactions: results of RECPAM analysis. A: Classes of patients with different mortality 
risks; B: Classes of patients with different disease progression risks. Chosen splitting 
variables are shown between branches, while condition sending patients to left or right sibling 
is on relative branch. Circles indicate subgroups of patients. Squares indicate RECPAM 
classes. Numbers inside circles and squares represent the number of events (top) and the 
number of non-events (bottom), respectively. The table placed at the bottom of the figures A-
B shows patients’ characteristics within each RECPAM class. Plot of survival curves, 
estimated from Cox proportional-hazards models, with respect to each identified RECPAM 
class for overall survival (panel A) and progression-free survival (panel B). 
When looking at the clinical pathological features of patients within each RECPAM classes 
(please see profiles at the bottom of Figure 2A), we found that pre-operative serum levels of 
CEA were higher in patients with lowest mortality risk (and vice versa) while, although not 
statistically significant, the percentage of subjects with jaundice and stage IIB-cancer patients 
was slight higher within intermediate and highest mortality risk classes. Interestingly, half of 
the patients with highest mortality risk had family history of cancer and were affected from 
diabetes mellitus, whereas about two-thirds of them were treated with gemcitabine for less 
than six cycles. On the other hand, a significantly higher percentage of patients with positive 
surgical margins were observed within intermediate risk class, as compared to the other 
classes (p = 0.007). 
Moreover, RECPAM algorithm also identified three classes at different disease-progression 
risk: as shown in Figure 2B, patients with hENT1 ≤ 0.11 (n = 3) identified the reference class 
(HR = 1), whereas those with hENT1 > 0.11 and DCK ≤ 1.43 (n = 14) identified the class 
with the highest disease-progression risk (Class 1, HR = 5.74, 95%CI = 1.01-32.43). 
Furthermore, patients with hENT1 > 0.11 and DCK > 1.43 (n = 9) identified the intermediate 
risk class (Class 2, HR = 1.63, 95%CI = 0.31-8.57). Disease progression rates (reported as the 
number of events per 100 person-years), along with median follow-up time, were: 90 (7.7 
months), 48 (11.2 months), 26 (23.0 months) for Classes 1,2 and 3, respectively. Figures 2A-
B reports survival curves, identified by RECPAM analyses for OS and PFS, respectively. 
When looking at the clinical pathological features of patients within each RECPAM classes 
(please see profiles at the bottom of Figure 2B), we found that patients with positive surgical 
margins belonged to Class 1 and 2, although no statistically significance was observed. 
When clinical variables were also included as candidate splitting variables, along with 
hENT1, CHOP, DCK, MRP1 genes, RECPAM tree-growing algorithm identified three 
classes at different mortality risks: as shown in Figure 3A, patients with DCK ≤ 0.27 (n = 6) 
identified the reference class (HR = 1), whereas those with DCK > 0.27 and received <6 
cycles of gemcitabine (n = 9) identified the class with the highest mortality risk (Class 1, HR 
= 21.41, 95%CI = 2.48-185.08). Furthermore, patients with DCK > 0.27 and received >6 
cycles of gemcitabine (n = 11) identified the intermediate risk class (Class 2, HR = 3.38, 
95%CI = 0.70-16.41). 
  
Figure 3 Identification of subgroups at different risks based on patients’ clinical 
features-gene expression interactions: results of RECPAM analysis. A: Classes of 
patients with different mortality risks; B: Classes of patients with different disease 
progression risks. Chosen splitting variables are shown between branches, while condition 
sending patients to left or right sibling is on relative branch. Circles indicate subgroups of 
patients. Squares indicate RECPAM classes. Numbers inside circles and squares represent the 
number of events (top) and the number of non-events (bottom), respectively. 
Similarly, RECPAM tree-growing algorithm identified three classes at different disease-
progression risks: as shown in Figure 3B, patients with lymph nodes ratio (LNM, i.e. the total 
involved lymph nodes among the total number of resected lymph nodes) ≤0.33 (n = 15) 
identified the reference class (HR = 1), whereas those with LNM >0.33 and MRP1 levels ≤ 
1.21 (n = 6) identified the class with the highest disease-progression risk (Class 1, HR = 
21.20, 95%CI = 3.55-126.75). Furthermore, patients with LMN > 0.33 and MRP1 levels > 
1.21 (n = 5) identified the intermediate risk class (Class 2, HR = 1.46, 95%CI = 0.36-5.95). 
Immunohistochemistry 
In order to perform a pilot evaluation of hENT1 protein localization/expression, 
immunohistochemical evaluations were carried out on 13 out of the 26 PDAC specimens 
used in the previous transcription analysis. Figure 4A and B shows 7 out of 13 selected 
representative immunoistochemistry of cases with highest hENT1 mRNA (1 V-15660), 
intermediate (1 M-17396; 193551–10 and I2012-016339) or lowest levels (1 T-17785; 1 
M17536 and I2011-010518) among all PDAC samples. Pathological features of these 
samples were listed in Table 2. hENT1 was mainly localized in the cytoplasm of the tumor 
cells. In particular, the strongest epithelial cell immunopositivity was observed in samples 
displaying the lowest hENT1 mRNA expression. By contrast, samples with an intermediate 
hENT1 mRNA expression showed a lower positivity for hENT1 protein that was present in 
approximately a half of the cancer cells. Finally the only sample with the highest hENT1 
mRNA expression (1V-15660) was negative for hENT1 protein immunopositivity (Figure 
4A-B). Strikingly, an inverse correlation between hENT1 mRNA and protein levels was 
found. In fact, tissue samples from PDAC patients with higher levels of hENT1 mRNA 
displayed lower levels of the protein and, conversely, PDAC samples with low hENT1 
protein levels showed higher levels of mRNA (Figure 4B). Noteworthy, normal pancreatic 
tissue displayed low hENT1 immunopositivity in the cytpoplasm and occasionally in the 
nuclei of the exocrine component (as indicated by the arrows in figure 4C) whereas high 
levels of hENT1 protein were observed in either cytoplasm and nuclei of the endocrine 
component. 
Figure 4 Inverse correlation between hENT1 protein and mRNA expression. A: 
Representative pictures of immunostainings performed for hENT1 protein in samples of 
randomly selected pancreatic ductal adenocarcinomas. The immunohistochemical results are 
indicated in a semiquantitative scale (−: 0%; +: 1-33%; ++: 34-66%; +++: 67-100%). 
Original magnifications: 400X. B: hENT1 mRNA expression levels in randomly selected 
pancreatic adenocarcinomas. C: representative pictures of immunostaining performed for 
hENT1 protein in control pancreatic tissue. 
Table 2 Pathological features of 7 patients with Pancreatic Ductal Adenocarcinoma included in the immunohistochemistry analysis 
 Age Gender Tumour type Tumour Size (cm) Tumour Grading Tumour stage Margins of resection 
1 V-15660 78 m PDAC 3.05 G2-G3 IIB R1 
1 M-17396 69 m Mucinous PDAC 3 G1 IIB R0 
1 M-17536 53 f PDAC 3 G2-G3 IIA R0 
1 T-17785 65 m PDAC 3 G2-G3 IIB R0 
193551-10 73 m PDAC 1,8 G1 IIB R0 
I2011-010518 51 f PDAC 2,5 G2 IIB R0 
I2012-016339 78 f PDAC 2,4 G2 IIB R0 
G1: well differentiated; G2: moderately differentiated; G3: poorly differentiated. R0: negative resection margins; R1:microscopic positive 
resection margins. Tumor stage sec. AJCC 2010. 
We propose the existence of a post-transcriptional feedback mechanism within PDAC cells 
that finely and reciprocally tune mRNA and protein levels of hENT1. In this respect, high 
levels of hENT1 mRNA in the most aggressive tumors could be part of a compensatory and 
adaptive mechanism. Mechanistic studies are warranted to support this hypothesis. 
Discussion 
Gemcitabine still represents the most common chemotherapeutic agent in the treatment of 
patients with PDAC [5,6]. However, nowadays cellular resistance to gemcitabine treatment 
represents the major problem in the clinical management of these patients [4]. Therefore, 
potential strategies to overcome and/or forecast chemoresistance are required in order to 
improve patient survival. In the present study, we examined gemcitabine related genes in a 
cohort of patients with PDAC underwent surgery and subsequent adjuvant treatment. To date 
a number of studies have evaluated hENT1 and other factors involved in gemcitabine 
pathway by means of functional assays in pancreatic cancer cell lines and/or human 
specimens mainly by using immunoistochemistry, and transcriptional analysis in few cases 
[24-28]. Anyhow, our study represents the first attempt to concurrently analyze, in a well 
selected population of PDAC patients, mRNA expression levels of hENT1 and other genes 
involved in gemcitabine pathway. In the overall sample we found a down-regulation of 
hENT1 and MRP1 in tumor compared to normal tissues, even though only hENT1 down-
regulation was statistically significant. On the other hand a substantially unchanged 
expression of DCK and CHOP emerged in our samples. Data on DCK were in line with those 
of Giovannetti and colleagues [28]. However, in this study, the authors found that hENT1 was 
over-expressed in tumor specimens from patients with pancreatic cancer. This difference 
could be explained by the different number of subjects considered in the two studies, as well 
as by the pathological characterization of clinical specimens and the surgical/oncological 
treatment of patients. 
In addition a direct correlation between levels of both hENT1 and CHOP with MRP1 
expression emerged. These data suggest that the role of hENT1 as main mediator of 
gemcitabine across plasma membrane could be also affected from expression of MRP1 in 
PDAC tumor tissues, directly or as result of CHOP transcriptional regulation. In relation to 
patient clinical phenotypes the most interesting findings concern differential expression levels 
of hENT1 with respect to the status of resection margins, a clinical pathological feature well 
recognized as prognostic factor of PDAC [29,30]. On the other hand, a significant association 
between hENT1 and jaundice at the diagnosis was observed. Jaundice represents the most 
common clinical symptom, albeit belated, of the disease, and has been also recently 
unraveled as a risk factor for diminished survival in patients with adenocarcinoma of the head 
of the pancreas [29]. Jaundice represents the most common clinical symptom, albeit belated, 
of the disease, and has been also recently unraveled as a risk factor for diminished survival in 
patients with adenocarcinoma of the head of the pancreas [31]. Significant correlations were 
also found for CHOP with respect to previous neoplasia and post-operative serum levels of 
CEA, one of the most common tumor markers used for clinical diagnosis of gastrointestinal 
and pancreatobiliary malignancies [32,33]. Finally, DCK down-regulation was associated 
with mucinous histotype of PDCA. Expression levels observed for the enzyme involved in 
gemcitabine phosphorylation/activation could explain the lower response to treatment 
observed in patients with mucinous disease compared to those without this pathological 
feature [34]. 
Several authors stated that higher hENT1 levels were associated with significantly longer 
overall survival and disease free survival in patients affected by pancreatic cancer [25-28]. As 
we mentioned above, the disagreement with data of Giovannetti and colleagues [28] may be 
due to the differences in patients enrolled in the two studies. Moreover in our cohort, hENT1 
mRNA expression was inversely correlated with the protein expression levels and this also 
could explain the discrepancy observed in the literature among the different studies 
[14,28,35]
.
 Our results, together with the previous observations, highlights that hENT1 
protein expression would be the most appropriate predictive marker. 
Nevertheless, in order to determine the usefulness of intratumoral expression of hENT1 and 
other factors involved in gemcitabine pathway as predictive markers of the efficacy of 
adjuvant gemcitabine-based chemotherapy for PDAC after operative resection, we used the 
RECPAM model to choose the natural cut-off points of genes expression levels for 
identification of patients at different-risk of mortality and disease progression. RECPAM 
analysis uncovered DCK and CHOP as the most important genes in distinguish patients with 
different mortality risk, while hENT1 and DCK were able to identify subgroups of patients 
with different disease progression risk. Using these RECPAM models to evaluate the possible 
effect/contribution of patient clinical profiles on gene expression alterations, we also tested a 
set of variables made of the suggested risk or prognostic factors for PDAC. 
Conclusion 
In this study we found that intermediate mortality risk was associated with positive surgical 
resected margins, whereas class of patients with high mortality risk was characterized by 
higher percentage of patients with different PDAC risk factors (family history). In relation to 
disease progression we showed that family history of neoplasia was associated. Our data 
suggested an interaction between DCK levels and the preoperative serum CEA levels and 
between preoperative serum CEA levels and tumor grading in relation to mortality and 
disease progression risk, respectively. Taken together all these data may help clinicians to 
classify disease behavior in PC patients, based on this gene expression pattern background. 
In this study we found that intermediate mortality risk was associated with positive surgical 
resected margins, whereas class of patients with high mortality risk was characterized by 
higher percentage of patients with different PDAC risk factors (family history for neoplasia 
although not significant). In addition, classes of patients with either intermediate or high risk 
of PDAC showed both to be characterized by an higher trend of jaundice and by tumors stage 
and unsuccessful gemcitabine induction phase. Indeed, also jaundice has been recently 
described as important, although poorly recognized risk factor for diminished survival in 
patients with adenocarcinoma of the pancreas [29]. Similarly, in relation to disease 
progression we showed that both positive resection margins and unsuccessful gemcitabine 
induction phase were present within the classes of patients at higher and intermediate risk 
although no statistical significance was observed. Finally, our data suggested an interaction 
between DCK levels and the number of cycles of gemcitabine and between lymph nodes 
metastases and MRP1 expression in relation to mortality and disease progression risk, 
respectively. Taken together all these data may help clinicians to classify disease behavior in 
PC patients, based on this gene expression pattern background. 
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